Johnson & Johnson (NYSE:JNJ) Shares Bought by OMNI 360 Wealth Inc.

OMNI 360 Wealth Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 57.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,221 shares of the company's stock after purchasing an additional 1,899 shares during the quarter. OMNI 360 Wealth Inc.'s holdings in Johnson & Johnson were worth $866,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Lantz Financial LLC increased its holdings in shares of Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $453,000. Joel Isaacson & Co. LLC increased its holdings in shares of Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares during the last quarter. State of Wyoming increased its holdings in shares of Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC increased its holdings in shares of Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after purchasing an additional 2,529 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Barclays lowered their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Trading Down 0.6%

Shares of JNJ traded down $0.91 during midday trading on Friday, hitting $156.78. 3,658,104 shares of the stock were exchanged, compared to its average volume of 8,043,817. The firm has a market cap of $377.21 billion, a P/E ratio of 17.44, a P/E/G ratio of 2.36 and a beta of 0.41. The stock has a fifty day simple moving average of $153.73 and a 200 day simple moving average of $154.35. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.32%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.